Becton, Dickinson and Company (NYSE:BDX) Updates FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $12.95-13.15 for the period, compared to the consensus EPS estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Analyst Ratings Changes

A number of research firms have recently commented on BDX. Barclays upped their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a research note on Monday, February 5th. Raymond James lifted their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an outperform rating in a research report on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $280.00.

Becton, Dickinson and Company Stock Up 2.8 %

BDX stock traded up $6.63 during trading on Thursday, reaching $240.35. 3,668,998 shares of the company traded hands, compared to its average volume of 1,410,217. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The company has a market capitalization of $69.44 billion, a price-to-earnings ratio of 56.95, a price-to-earnings-growth ratio of 1.94 and a beta of 0.45. The business has a 50 day simple moving average of $238.68 and a 200 day simple moving average of $240.71. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company had revenue of $5.05 billion during the quarter, compared to analysts' expectations of $5.04 billion. During the same period in the prior year, the business earned $2.86 EPS. The firm's quarterly revenue was up 4.6% on a year-over-year basis. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.58%. Becton, Dickinson and Company's dividend payout ratio is presently 90.05%.

Insider Activity at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the firm's stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.